Literature DB >> 29457085

A case in which a capnometer was useful for diagnosing laryngospasm following administration of sugammadex.

Keito Kou1, Takeshi Omae1, Saiko Wakabayashi1, Sonoko Sakuraba1.   

Abstract

BACKGROUND: Sugammadex has been reported to cause upper-airway obstruction, such as laryngospasm or bronchospasm. These two conditions are treated using different approaches, but the differential diagnosis is difficult. CASE
PRESENTATION: We describe a case in which general anesthesia was administered via endotracheal intubation, in combination with brachial-plexus block, for arthroscopic surgical treatment of a rotator-cuff tear caused by recurrent shoulder dislocation. The total dose of rocuronium administered was 90 mg, and the last dose of 10 mg was given 15 min before the end of the surgery. Sugammadex was intravenously administered at 100 mg to reverse the effect of rocuronium after the operation ended. After extubation in this case, we placed a mask firmly around the patient's mouth, and thus, there was no air leakage around the mask. We detected upper-airway obstruction that was presumably attributable to administration of sugammadex. The end-tidal carbon dioxide (EtCO2) concentration was undetectable on a capnometer. Although 100% oxygen was administered at 10 L/min via a facemask, oxygen saturation (SpO2) decreased to approximately 70%. With suspected onset of laryngospasm, continuous positive airway pressure with 100% oxygen at 10 L/min was started at 30 cm H2O. The patient's airway obstruction resolved after a short time.
CONCLUSION: The use of a capnometer facilitated the diagnosis of laryngospasm and allowed us to administer appropriate treatment after administration of sugammadex.

Entities:  

Keywords:  Bronchospasm; Capnometer; Continuous positive airway pressure; Rocuronium; Sugammadex

Year:  2017        PMID: 29457085      PMCID: PMC5804625          DOI: 10.1186/s40981-017-0111-8

Source DB:  PubMed          Journal:  JA Clin Rep        ISSN: 2363-9024


Background

Sugammadex, an antagonist of muscle relaxants, has been reported to cause upper airway obstruction, such as laryngospasm [1-3] or bronchospasm [3, 4]. We herein report our experience with a case in which a capnometer was useful for the differential diagnosis of upper airway obstruction following administration of sugammadex.

Case presentation

A 25-year-old man with a height of 168 cm and weight of 68 kg underwent arthroscopic surgery to treat a rotator cuff tear caused by recurrent shoulder dislocation. He had no remarkable medical history. General anesthesia was induced with propofol (100 mg), remifentanil (0.3 μg/kg/min), and rocuronium (40 mg), while an 8.0-mm endotracheal tube was inserted for airway management. Additionally, a brachial plexus block was administered with 0.25% levobupivacaine (30 mL) through an interscalene approach under ultrasonographic guidance, and an indwelling catheter was placed. While the patient was placed in the beach-chair position during surgery, anesthesia was maintained with oxygen 1 L/min, air 2 L/min, 1.5% sevoflurane, and remifentanil 0.2-0.3 μg/kg/min. The patient was monitored using five-lead electrocardiography, pulse oximetry, and capnometry. The total dose of rocuronium administered was 90 mg, and the last dose of 10 mg was given 15 min before the end of the surgery. The operative time was 3 h and 21 min. Continuous infusion of remifentanil was discontinued simultaneous with the end of surgery. Administration of sevoflurane was discontinued 5 min later. Sugammadex was intravenously administered at 100 mg to reverse rocuronium. Since the patient regained clear consciousness and spontaneous breathing at 10 mL/kg, the intubation tube was removed. Immediately after extubation, he presented with retractive breathing and stridor. According to the capnometer readings, the end-tidal carbon dioxide (EtCO2) concentration was undetectable. Although 100% oxygen was administered at 10 L/min via a facemask, oxygen saturation (SpO2) decreased to approximately 70%. Onset of laryngospasm was suspected, and thus, 100% oxygen was started at 10 L/min with continuous positive airway pressure (30 cm H2O). The patient’s airway was reopened after a while. Consequently, both stridor and retractive breathing resolved. The EtCO2 waveforms became detectable with a capnometer, and SpO2 also improved to 100% (Fig.1). The patient was monitored in the operating room for 30 min. After a stable level of consciousness and stable respiratory patterns were confirmed, he was discharged from the operating room. No recurrence of laryngospasm was observed throughout the postoperative course.
Fig. 1

Changes in end-tidal carbon dioxide and arterial oxygen saturation of pulse oxymetry after sugammadex administration. Event: ① intravenous injection of sugammadex, ② extubation, ③ disappearance of end-tidal carbon dioxide (EtCO2), ④ decline of arterial oxygen saturation, ⑤ start of continuous positive airway pressure

Changes in end-tidal carbon dioxide and arterial oxygen saturation of pulse oxymetry after sugammadex administration. Event: ① intravenous injection of sugammadex, ② extubation, ③ disappearance of end-tidal carbon dioxide (EtCO2), ④ decline of arterial oxygen saturation, ⑤ start of continuous positive airway pressure

Discussion

This patient presented with retractive breathing, stridor, and decreased SpO2 immediately after extubation. We suspected that these symptoms were attributable to bronchospasm or laryngospasm associated with administration of sugammadex. It has been reported that sugammadex may cause bronchospasm [3]. This is reportedly more likely in patients with a history of respiratory disease, such as bronchial asthma. Meanwhile, bronchospasm is triggered by various mechanical (e.g., endotracheal intubation), chemical, and pharmacological stimuli. While its intraoperative respiratory adverse event is approximately 1.7%, bronchospasm and laryngospasm are complications in which deaths have been reported in some severe cases [5-7]. The most common pathological condition recognized as bronchospasm is asthma. When considering the treatment for bronchospasm, volatile anesthetic agents are useful because with the exception of desflurane, they have a bronchodilator effect [8]. Desflurane increases airway resistance at a high alveolar concentration [8]. When bronchospasm is severe, it is difficult to use volatile anesthetic agents. Propofol relaxes the airway reflex [9]. Beta-stimulants, such as salbutamol and epinephrine, can also be administered intravenously [10]. Anticholinergic drugs, such as tiotropium bromide, block parasympathetic constriction of bronchial smooth muscle [11]. Intravenous magnesium sulfate is also effective for bronchospasm [12]. Laryngospasm is defined as glottis narrowing caused by reflective contraction of the laryngeal muscles. It is classified into complete and incomplete types. The complete type is referred to as a condition in which the immobility of the back leads to complete failure of ventilation, whereas the incomplete type is referred to as a condition in which the motion of the thorax is accompanied by inspiratory stridor and limited motion of the back. When incomplete laryngospasm progresses to the complete type, inspiratory stridor disappears [13, 14]. Laryngospasm frequently occurs in ambulatory anesthesia [15], while its occurrence has also been reported during orthopedic surgery [16, 17], laparotomy [16], and craniotomy [18]. Laryngospasm is more common in young people than in adults. In fact, its incidence has been reported to reach 14% in those aged less than 6 years [19]. A definitive diagnosis of this condition is made by examination of the vocal cords with a bronchial fiberscope [20]. When laryngospasm is diagnosed, the irritating stimulus by any triggering factor should be removed. Positive-pressure ventilation with 100% oxygen, which forces the chin forward with strong pressure from behind the ascending rami of the jaw, is required for laryngospasm [21]. When this fails, endotracheal intubation is required. Anesthesia should be deepened with an intravenous anesthetic. For endotracheal intubation, succinylcholine is widely used as a muscle relaxant [21]. It has been reported that succinylcholine is administered to avoid significant hypoxia in approximately 25 to 50% of these cases [22]. If it is difficult to intubate using an endotracheal tube, cricothyroidotomy or tracheotomy is needed to access the airway rapidly [23]. Prolonged laryngospasm may cause serious complications, such as cardiac arrest, aspiration, and negative pressure pulmonary edema [23]. Bronchospasm and laryngospasm should be differentiated soon after onset because they differ in terms of treatment strategies and subsequent complications. In our case, a capnometer was useful for differentiating between bronchospasm and laryngospasm. Although a definitive diagnosis of laryngospasm is made by examination of the vocal cords with a bronchial fiberscope [20], there was insufficient time to perform bronchial fiberscopy in order to prevent progression to NPPE. No waveform appears in capnometer readings of laryngospasm, which causes complete occlusion of the upper respiratory tract; however, they reveal waveform patterns of occlusive respiratory disorders and provide EtCO2 values in most cases of bronchospasm. In our case, laryngospasm was diagnosed because EtCO2 waveforms were absent on the capnometer readings, and continuous positive airway pressure with 100% oxygen was applied through a facemask, resulting in relief of symptoms. Because there are reported cases of NPPE that occurred a few hours after extubation [24], adequate follow-up is necessary. However, our patient presented with neither subjective symptoms nor abnormal radiographic findings after surgery.

Conclusions

After extubation in this case, we detected upper airway obstruction that was presumably attributable to administration of sugammadex. The treatment strategies for upper airway obstruction vary depending on the cause. The use of a capnometer facilitated the diagnosis of laryngospasm and allowed us to administer appropriate treatment.
  24 in total

Review 1.  Review of guidelines and the literature in the treatment of acute bronchospasm in chronic obstructive pulmonary disease.

Authors:  Roy A Pleasants
Journal:  Pharmacotherapy       Date:  2006-09       Impact factor: 4.705

2.  Perioperative Respiratory Adverse Events in Pediatric Ambulatory Anesthesia: Development and Validation of a Risk Prediction Tool.

Authors:  Rajeev Subramanyam; Samrat Yeramaneni; Mohamed Monir Hossain; Amy M Anneken; Anna M Varughese
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

3.  Use of sugammadex in patients with a history of pulmonary disease.

Authors:  Rasheed Amao; Mark H Zornow; Robert McTaggart Cowan; Davy C Cheng; Jovino B Morte; Martin W Allard
Journal:  J Clin Anesth       Date:  2012-06       Impact factor: 9.452

Review 4.  Problems associated with tracheal extubation.

Authors:  M Hartley; R S Vaughan
Journal:  Br J Anaesth       Date:  1993-10       Impact factor: 9.166

Review 5.  Tiotropium bromide.

Authors:  Karen M Hvizdos; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Pulmonary edema following post-operative laryngospasm: a case report and review of the literature.

Authors:  K D Halow; E G Ford
Journal:  Am Surg       Date:  1993-07       Impact factor: 0.688

Review 7.  Negative-Pressure Pulmonary Edema.

Authors:  Mallar Bhattacharya; Richard H Kallet; Lorraine B Ware; Michael A Matthay
Journal:  Chest       Date:  2016-04-08       Impact factor: 9.410

8.  Risk factors for laryngospasm in children during general anesthesia.

Authors:  Randall P Flick; Robert T Wilder; Stephen F Pieper; Kevin van Koeverden; Kyle M Ellison; Mary E S Marienau; Andrew C Hanson; Darrell R Schroeder; Juraj Sprung
Journal:  Paediatr Anaesth       Date:  2008-04       Impact factor: 2.556

9.  Upper airway reflexes during a combination of propofol and fentanyl anesthesia.

Authors:  Y Tagaito; S Isono; T Nishino
Journal:  Anesthesiology       Date:  1998-06       Impact factor: 7.892

Review 10.  Sugammadex and rocuronium-induced anaphylaxis.

Authors:  Tomonori Takazawa; Hiromasa Mitsuhata; Paul Michel Mertes
Journal:  J Anesth       Date:  2015-12-08       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.